Illumina (ILMN) Stock Forecast & Price Target

Compare

4,618 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ILMN Analyst Ratings

Hold

4 Buy

6 Hold

3 Sell

Based on 13 analysts giving stock ratings to

Illumina

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ILMN Stock 12 Month Forecast

Average Price Target

$129.81

▲(6.84% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $129.81 with a high forecast of $170.00 and a low forecast of $40.50. The average price target represents a 6.84% change from the last price of $121.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","72":"$72","105":"$105","138":"$138","171":"$171"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,72,105,138,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.89,135.74461538461537,138.59923076923076,141.45384615384614,144.30846153846153,147.16307692307691,150.0176923076923,152.8723076923077,155.72692307692307,158.58153846153846,161.43615384615384,164.29076923076923,167.14538461538461,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.89,132.65307692307692,132.41615384615383,132.17923076923077,131.94230769230768,131.70538461538462,131.46846153846153,131.23153846153846,130.99461538461537,130.7576923076923,130.52076923076922,130.28384615384616,130.04692307692306,{"y":129.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.89,125.7830769230769,118.67615384615384,111.56923076923076,104.46230769230769,97.35538461538461,90.24846153846153,83.14153846153846,76.03461538461538,68.9276923076923,61.82076923076923,54.71384615384615,47.60692307692307,{"y":40.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.13,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$170.00

Average Price Target$129.81

Lowest Price Target$40.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

$150

Hold

23.46%

Upside

Reiterated

03/08/26

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX) and Illumina (NASDAQ: ILMN)We reiterate our HOLD rating on Illumina (ILMN) and maintain our $150 price target. With this note, we provide background and our views (e.g., share shift and intrinsic value scenarios) on the potential impact of Roche's entrance into the short-read sequencing industry. In particular, Roche's announcement of its AXELIOS short-read sequencer introduces a credible new competitor to Illumina’s core franchise. Roche expects to launch the platform in summer 2026 at an estimated $150 per genome price point. While the announcement raises the possibility of incremental pricing pressure and future share competition, our market share scenarios, revenue modeling and DCF sensitivity analysis suggest that the near-term financial impact to Illumina is likely modest.

Michael Ryskin

Bank of America Securities

$85

Sell

-30.04%

Downside

Reiterated

03/02/26

Bank of America Securities Reaffirms Their Sell Rating on Illumina (ILMN)

Subbu Nambi

Guggenheim

$170

Buy

39.92%

Upside

Reiterated

02/23/26

Guggenheim Keeps Their Buy Rating on Illumina (ILMN)

David Westenberg

Piper Sandler

$195→$170

Buy

39.92%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN), Veeva Systems (VEEV)

Daniel Brennan

TD Cowen

$140

Hold

15.23%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Illumina (NASDAQ: ILMN) and Rigel (NASDAQ: RIGL)

Dan Leonard

UBS

$120→$135

Hold

11.11%

Upside

Reiterated

02/06/26

Illumina price target raised to $135 from $120 at UBSIllumina price target raised to $135 from $120 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$132→$137

Hold

12.76%

Upside

Reiterated

02/06/26

Illumina price target raised to $137 from $132 at BairdIllumina price target raised to $137 from $132 at Baird

Vijay Kumar

Evercore ISI

$155→$150

Buy

23.46%

Upside

Reiterated

02/06/26

Illumina price target lowered to $150 from $155 at Evercore ISIIllumina price target lowered to $150 from $155 at Evercore ISI

Daniel Arias

Stifel Nicolaus

$155

Buy

27.57%

Upside

Reiterated

02/06/26

Illumina (ILMN) Gets a Buy from Stifel Nicolaus

Casey Woodring

J.P. Morgan

$130→$120

Hold

-1.23%

Downside

Reiterated

02/06/26

Illumina price target lowered to $120 from $130 at JPMorganIllumina price target lowered to $120 from $130 at JPMorgan

Luke Sergott

Barclays

$110

Sell

-9.47%

Downside

Reiterated

02/06/26

Illumina (ILMN) Gets a Sell from Barclays

Patrick B Donnelly

Citi

$80→$40.5

Sell

-66.67%

Downside

Reiterated

01/02/26

Citi Reaffirms Their Sell Rating on Illumina (ILMN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$108→$125

Hold

2.88%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Hold Rating for Illumina (ILMN)

Conor McNamara

RBC Capital

$126→$124

Buy

2.06%

Upside

Reiterated

09/02/25

Illumina (ILMN) Receives a Buy from RBC Capital

Narumi Nakagiri

Daiwa

$94

Hold

-22.63%

Downside

Downgraded

08/12/25

Illumina downgraded to Neutral from Outperform at DaiwaIllumina downgraded to Neutral from Outperform at Daiwa

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

$150

Hold

23.46%

Upside

Reiterated

03/08/26

Michael Ryskin

Bank of America Securities

$85

Sell

-30.04%

Downside

Reiterated

03/02/26

Bank of America Securities Reaffirms Their Sell Rating on Illumina (ILMN)

Subbu Nambi

Guggenheim

$170

Buy

39.92%

Upside

Reiterated

02/23/26

Guggenheim Keeps Their Buy Rating on Illumina (ILMN)

David Westenberg

Piper Sandler

$195→$170

Buy

39.92%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN), Veeva Systems (VEEV)

Daniel Brennan

TD Cowen

$140

Hold

15.23%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Illumina (NASDAQ: ILMN) and Rigel (NASDAQ: RIGL)

Dan Leonard

UBS

$120→$135

Hold

11.11%

Upside

Reiterated

02/06/26

Illumina price target raised to $135 from $120 at UBSIllumina price target raised to $135 from $120 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$132→$137

Hold

12.76%

Upside

Reiterated

02/06/26

Illumina price target raised to $137 from $132 at BairdIllumina price target raised to $137 from $132 at Baird

Vijay Kumar

Evercore ISI

$155→$150

Buy

23.46%

Upside

Reiterated

02/06/26

Illumina price target lowered to $150 from $155 at Evercore ISIIllumina price target lowered to $150 from $155 at Evercore ISI

Daniel Arias

Stifel Nicolaus

$155

Buy

27.57%

Upside

Reiterated

02/06/26

Illumina (ILMN) Gets a Buy from Stifel Nicolaus

Casey Woodring

J.P. Morgan

$130→$120

Hold

-1.23%

Downside

Reiterated

02/06/26

Illumina price target lowered to $120 from $130 at JPMorganIllumina price target lowered to $120 from $130 at JPMorgan

Luke Sergott

Barclays

$110

Sell

-9.47%

Downside

Reiterated

02/06/26

Illumina (ILMN) Gets a Sell from Barclays

Patrick B Donnelly

Citi

$80→$40.5

Sell

-66.67%

Downside

Reiterated

01/02/26

Citi Reaffirms Their Sell Rating on Illumina (ILMN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$108→$125

Hold

2.88%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Hold Rating for Illumina (ILMN)

Conor McNamara

RBC Capital

$126→$124

Buy

2.06%

Upside

Reiterated

09/02/25

Illumina (ILMN) Receives a Buy from RBC Capital

Narumi Nakagiri

Daiwa

$94

Hold

-22.63%

Downside

Downgraded

08/12/25

Illumina downgraded to Neutral from Outperform at DaiwaIllumina downgraded to Neutral from Outperform at Daiwa

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Illumina

3 Months

xxx

Success Rate

20/38 ratings generated profit

Average Return

+2.77%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +2.77% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

14/24 ratings generated profit

Average Return

+0.84%

reiterated a sell rating 12 days ago

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +0.84% per trade.

2 Years

xxx

Success Rate

17/31 ratings generated profit

Average Return

-0.78%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 54.84% of your transactions generating a profit, with an average return of -0.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ILMN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ILMN has received 14 Buy Ratings, 33 Hold Ratings, and 6 Sell Ratings. ILMN average Analyst price target in the past 3 months is 129.81.

Each month's total comprises the sum of three months' worth of ratings.

ILMN Financial Forecast

ILMN Earnings Forecast

Next quarter’s earnings estimate for ILMN is $1.06 with a range of $1.04 to $1.14. The previous quarter’s EPS was $1.35. ILMN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ILMN has Performed in-line its overall industry.

ILMN Sales Forecast

Next quarter’s sales forecast for ILMN is $1.07B with a range of $1.06B to $1.08B. The previous quarter’s sales results were $1.16B. ILMN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ILMN has Performed in-line its overall industry.

ILMN Stock Forecast FAQ

What is ILMN’s average 12-month price target, according to analysts?

Based on analyst ratings, Illumina’s 12-month average price target is 129.81.

What is ILMN’s upside potential, based on the analysts’ average price target?

Illumina has 6.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ILMN a Buy, Sell or Hold?

Illumina has a consensus rating of Hold which is based on 4 buy ratings, 6 hold ratings and 3 sell ratings.

What is Illumina’s price target?

The average price target for Illumina is 129.81. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $170.00 ,the lowest forecast is $40.50. The average price target represents 6.84% Increase from the current price of $121.5.

What do analysts say about Illumina?

Illumina’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ILMN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Illumina (ILMN) Stock Forecast & Price Target

ILMN Analyst Ratings

ILMN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Illumina

ILMN Analyst Recommendation Trends

ILMN Financial Forecast

ILMN Earnings Forecast

ILMN Sales Forecast

ILMN Stock Forecast FAQ

Detailed List of Analyst Forecasts